Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF

Introduction: Relaxin-1 (RLN1) has emerged as a possible therapeutic target in myocardial fibrosis due to its anti-fibrotic effects. Previous randomized clinical trials investigated therapeutic role of exogenous relaxin in patients with acute-on-chronic heart failure (HF) and failed to meet clinical...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Physiol
Autors principals: Simon, Judit, Nemeth, Endre, Nemes, Annamaria, Husveth-Toth, Maria, Radovits, Tamas, Foldes, Gabor, Kiss, Loretta, Bagyura, Zsolt, Skopal, Judit, Merkely, Bela, Gara, Edit
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Physiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558211/
https://ncbi.nlm.nih.gov/pubmed/31231242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2019.00690
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars